Aastrom Biosciences, Inc. is a regenerative medicine company and focuses on
the clinical development of autologous cell products for the repair or
regeneration of multiple human tissues, based on its Tissue Repair Cell
(TRC) technology. The Company's preclinical and clinical product development
programs utilize patient-derived bone marrow stem and early progenitor cell
populations and are investigated for their ability to aid in the
regeneration of tissues, such as cardiac, vascular and bone. TRC-based
products have been used in over 350 patients, and its stages of development
are Cardiac regeneration includes Cardiac Repair Cells (CRCs); Dilated
cardiomyopathy (DCM) (severe heart failure); Vascular regeneration includes
Vascular Repair Cells (VRCs); Critical limb ischemia (CLI); Bone
regeneration includes Bone Repair Cells (BRCs); Osteonecrosis of the femoral
head; Non-union fractures, and Maxillofacial.